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Abstract: Ovarian cancer is a highly lethal disease, mainly due to chemoresistance. Our previous 
studies on metabolic remodeling in ovarian cancer have supported that the reliance on glutathione 
(GSH) bioavailability is a main adaptive metabolic mechanism, also accounting for chemoresistance 
to conventional therapy based on platinum salts. In this study, we tested the effects of the in vitro 
inhibition of GSH synthesis on the restoration of ovarian cancer cells sensitivity to carboplatin. GSH 
synthesis was inhibited by exposing cells to L-buthionine sulfoximine (L-BSO), an inhibitor of γ-
glutamylcysteine ligase (GCL). Given the systemic toxicity of L-BSO, we developed a new 
formulation using polyurea (PURE) dendrimers nanoparticles (L-BSO@PUREG4-FA2), targeting L-
BSO delivery in a folate functionalized nanoparticle.  
Keywords: ovarian cancer; chemoresistance; L-buthionine sulfoximine; polyurea dendrimers; 
carboplatin; nanoparticles-mediated chemotherapy; chemosensitization 
 
1. Introduction 
Ovarian cancer is a highly mortal gynecologic cancer [1–3], with the late diagnosis and acquired 
chemoresistance to the conventional therapy as the major hurdles to cure this disease [4–6]. The 
conventional therapy of ovarian cancer is mainly based on comprehensive oxidative/alkylating drugs 
such as carboplatin in combination with taxanes [7–9]. The platinum drugs induce cell death through 
two mechanisms: the establishment of adducts of DNA and proteins, and the generation of reactive 
oxygen species (ROS) [9,10]. We have previously found that ovarian cancer cells exhibit a great 
metabolic reliance on cysteine and glutathione (GSH), as these thiols were shown to protect cells 
under stressful conditions such as hypoxia or carboplatin exposure, hence, also accounting for 
chemoresistance [11–13]. GSH can explain this protective effect given its role as a ROS scavenger and 
as a pivotal drug detoxifier, allowing cells to evade cell death [14–18]. We have reported that 
chemoresistance, supported by high GSH levels, can be abrogated upon the exposure to L-buthionine 
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sulfoximine (L-BSO) [11], an inhibitor of γ-glutamylcysteine ligase (GCL), the first enzyme catalyzing 
the synthesis of GSH [19,20]. However, the systemic administration of L-BSO is associated to an 
elevated toxicity, since L-BSO is an irreversible inhibitor of GCL [19]. Therefore, an appropriate 
approach to revert this systemic toxicity would be the targeted delivery of L-BSO to cancer cells using 
a nanoparticles-mediated strategy. In this sense, dendrimers are an outstanding drug delivery 
platform, and many efforts have been made in the last few years to circumvent their cytotoxicity [21], 
encouraging the fast translation into clinic applications in a near future. In this study, we developed 
polyurea (PURE) dendrimers, which are a special case of non-toxic [22] and non-hemolytic 
dendrimers up to very high concentrations (circa 50 μM, unpublished data), and that have already 
been explored in different nanotherapeutic strategies [23–26]. The use of folate-targeted dendrimers 
is an emergent approach in cancer-targeted chemotherapy [27]. As we recently reported [28], folate-
targeted polyurea dendrimer generation four (PUREG4-FA2) nanoparticles are a suitable drug 
delivery system. Of notice, ovarian cancer cells express higher levels of folate receptor α (FA-Rα) than 
normal cells [29] and FA-Rα targeted therapy is an assay commonly tested in in vitro and in vivo 
models of ovarian cancer [30]. In here, we hypothesized that PUREG4-FA2 encapsulated L-BSO (L-
BSO@PUREG4-FA2) is a suitable strategy to tackle carboplatin resistance, restoring ovarian cancer cells 
sensitivity to chemotherapy. 
2. Materials and Methods 
2.1. Cell Culture  
Two human ovarian cancer cell lines were used, a serous carcinoma (OSC) cell line (OVCAR3-
HTB-161™) and a clear cell carcinoma (OCCC) cell line (ES2-CRL-1978™). In order to analyze the 
effect of nanoparticles in squamous cells, since ovarian cancer metastasizes preferentially to 
peritoneum, an immortalized squamous epithelium cell line (HaCaT-PCS-200-011™) was also tested. 
All the cell lines were obtained from American Type Culture Collection (ATCC) (Manassas, VA, USA) 
and were cultured in Dulbecco’s Modified Eagel Medium (DMEM; 41965-039, Gibco, Life 
Technologies; Massachusetts, MA, USA). All culture media were supplemented with 10% fetal 
bovine serum (FBS; S 0615, Merck; Darmstadt, Germany), 1% Antibiotic-Antimycotic (AA; P06-07300, 
PAN Biotech; Aidenbach, Germany) and 50 µg/mL gentamicin (15750-060, Gibco, Life Technologies; 
Massachusetts, MA, USA). Cells were maintained in a humidified environment of 5% CO2 at 37 °C, 
until reaching approximately 75–100% optical confluence. Cells were detached with 0.05% Trypsin-
EDTA (25300-054, Invitrogen, Thermo Fisher Scientific; Massachusetts, MA, USA) at room 
temperature (RT) for approximately 5 min, and split to new plates according to the experimental 
procedures.  
2.2. Folate Receptor α (FA-Rα) Immunofluorescence  
Sections of 4% paraformaldehyde fixed and paraffin embedded cells (cyto-blocks) were used, 
after deparaffinization in xylol and re-hydration in a sequence of 5 min incubations in 100%, 70% and 
40% ethanol, followed by 10 min in water. Slides were then incubated with the mouse-anti-human 
FA-Rα (IPI3005G10, BioCare Medical; Pacheco, CA, USA) for 3 h at RT; followed by incubation with 
the rabbit-anti-mouse Alexa Fluor® 488-conjugated secondary antibody (A-28175, Invitrogen; 
Massachusetts, MA, USA), 1 h, in the dark, at RT. Slides were mounted in VECTASHIELD media 
containing DAPI (4′-6-diamidino-2-phenylindole) to counterstain cell nuclei in blue (H-1200, Vector 
Labs; Burlingame, CA, USA). The analysis was performed by standard fluorescence microscopy in 
an Axio Imager.Z1 microscope (Zeiss, Oberkochen, Germany). Images were acquired and processed 
with CytoVision software (Leica, Wetzlar, Germany). 
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2.3. L-BSO and FL Encapsulation  
Polyurea (PURE) dendrimers were synthesized following our supercritical-assisted 
polymerization methodology [22]. FA-NHS and PUREG4-FA2 were synthesized following our 
reported protocol [31]. All chemicals and solvents were used as received without further purification. 
Folic acid (FA) and N,N-dicyclohexylcarbodiimide (DCC; A10973) (99% purity) were obtained from 
Alfa Aesar (Kandel, Germany). Fluorescein (FL; F7505), Triethylamine (TEA; 471283) (≥99.5% purity), 
N-hydroxysuccinimide (NHS; 130672) (98% Purity) and L-buthionine sulfoximine (L-BSO: B2515) 
(≥97% purity) were obtained from Sigma-Aldrich (Darmstadt, Germany).  
The encapsulation of FL in PUREG4-FA2 (FL@PUREG4-FA2) followed the same methodology used 
for L-BSO encapsulation [31]. Typically, in a vial, FL (0.0131 mmol, 5.3 mg) was dissolved in 1 mL of 
distilled water. To this solution, the folate-target dendrimer (PUREG4-FA2) (6.46 µmol, 56.6 mg) was 
added. The mixture was then left overnight at RT, in the dark, and under stirring. After this period, 
the product was purified by dialysis (MWCO 100–500 Da) and characterized by 1H NMR.  
2.4. Confirmation of Cellular Internalization of Nanoparticles by Flow Cytometry 
Cells (1 × 105 cells/well) were cultured overnight on 24-well plates and then incubated with 
several concentrations of FL@PUREG4-FA2 (0.001–0.120 µM) for 24 h. Only viable adherent cells were 
collected for the analysis. Cells were then washed with PBS (1×) and detached with trypsin-EDTA. 
After collection to 1.5 mL Eppendorfs, cells were harvested by centrifugation at 255× g for 3 min and 
washed twice with PBS (1×). Afterwards, cells were suspended in 200 µL of PBS (1×) and samples 
were analyzed by flow cytometry (FACScalibur–Becton Dickinson; New Jersey, NJ, USA). Sample 
data was analyzed using FlowJo 8.7 software (https://www.flowjo.com). The assay was performed at 
least in three biological replicates.  
2.5. Confirmation of Cellular Internalization of Nanoparticles by Fluorescence Microscopy  
The cell lines OVCAR3, ES2 and HaCaT were cultured on glass slides coated with 0.2% gelatine 
and then incubated with free FL or FL@PUREG4-FA2, for 8 and 24 h. After incubation, cells were fixed 
in 2% paraformaldehyde for 15 min at RT and washed with PBS (1×). The slides were mounted in 
VECTASHIELD media with DAPI and examined by standard fluorescence microscopy using an Axio 
Imager.Z1 microscope. The images were acquired with the CytoVision software. The assay was 
performed at least in three biological replicates. 
2.6. Cell Death Analysis by Flow Cytometry  
The cells (1 × 105 cells/well) were seeded in 24-well plates and cultured overnight in control 
conditions. The effect of different concentrations of free L-BSO (between 0.05 and 120 mM) and L-
BSO@PUREG4-FA2 (between 3 and 2522 µM) in cell viability was tested for 24 h of exposure. To 
evaluate the sensitization effect of L-BSO to carboplatin, OVCAR3 cells were exposed to the previous 
culture conditions combined with carboplatin (25 µg/mL).  
After experimental conditions, the detached cells in supernatants were collected, and adherent 
cells were harvested with 0.05% Trypsin-EDTA. Cells in the supernatant and trypsinized cells were 
harvested together by centrifugation, 255× g for 2 min. Cells were stained with 0.5 µL annexin V-
fluorescein (FITC)-(640906, BioLegend, San Diego, CA, USA), in 1× annexin V binding buffer (10 mM 
HEPES—pH 7.4, 150 mM NaCl, 2.5 mM CaCl2, prepared in 1× PBS—pH 7.4), and incubated at RT, in 
the dark, for 15 min. Samples were resuspended in 200 µL PBS (1×) plus 1% BSA and centrifuged at 
255× g for 2 min. Cells were resuspended in 200 µL of annexin V binding buffer 1× and 2.5 µL of 
propidium iodide (PI, 50 µg/mL; P4170, Sigma-Aldrich; Darmstadt, Germany) was added 5 min prior 
to analysis. Afterwards, samples were analyzed by flow cytometry (FACScalibur–Becton Dickinson; 
Franklin Lakes, NJ, USA). Data were analyzed using FlowJo 8.7 software (https://www.flowjo.com). 
The assay was performed at least in three biological replicates.  
2.7. Statistical Analysis  
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Statistical analyses were performed in GraphPad Prism 7.0 software (www.graphpad.com). Data 
is presented as mean ± SD. Assays were performed with at least three biological replicates. For 
comparisons of two groups, two-tailed unpaired t-test was used. To compare more than two groups, 
one-way and two-way analysis of variance (ANOVA) with Dunnets multiple-comparisons test were 
used. Statistical significance was established at p < 0.05; * p < 0.05, ** p < 0.01, *** p < 0.001, **** p < 
0.0001. 
3. Results 
3.1. Ovarian Cancer Cells Internalize PUREG4-FA2 Nanoparticles in a Dose Dependent Manner 
The expression of FA-Rα was confirmed in ovarian cancer (ES2 and OVCAR3) and squamous 
non-cancer (HaCaT) cell lines. As seen, HaCaT cell are negative for FA-Rα, whereas ES2 and 
OVCAR3 cells express FA-Rα (Figure 1Α). In order to validate the specificity of the internalization of 
PUREG4-FA2 by ovarian cancer cells, we tested fluorescein loaded PUREG4-FA2 (FL@PUREG4-FA2) 
prior to test L-BSO@PUREG4-FA2. By flow cytometry and fluorescence microscopy, we verified that 
FL is delivered in a dose dependent manner to both ES2 and OVCAR3 cell lines (Figure 1). In HaCaT 
cells, the internalization of fluorescein was only verified at the highest concentration (1 µM) of 
FL@PUREG4-FA2, after 8 and 24 h (Figure 1C,D). This observation supports the affinity of FL@PUREG4-
FA2 to ovarian cancer cells. 
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Figure 1. Ovarian cancer cells internalize FL@PUREG4-FA2 nanoparticles in a dose dependent manner. 
The expression of folate receptor α (FA-Rα) was evaluated by immunofluorescence in HaCaT, ES2 
and OVCAR3 cells (A). Ovarian cancer cells (OVCAR3 and ES2) were exposed to different 
concentrations of PUREG4-FA2 nanoparticles loaded with fluorescein (FL@PUREG4-FA2) and the 
cellular internalization was confirmed by: (B) FL fluorescence detected by flow cytometry (after 24 h 
of incubation); and by fluorescence microscopy (C) after 8 h and (D) 24 h of incubation. HaCaT cells 
were used as a control in fluorescence microscopy. In immunofluorescence, nuclei were DAPI (4′,6-
diamidino-2-phenylindole) counterstained. Results are shown as mean ± SD. ** p ≤ 0.01  **** p ≤ 0.0001. 
3.2. L-BSO@PUREG4-FA2 is More Effective in Inducing Cell Death in Ovarian Cancer Cells than Free L-BSO 
The efficacy of inducing cell death by free and encapsulated L-BSO was tested in ovarian cancer 
cells, in order to verify the advantages of using a L-BSO targeted delivery. In ovarian cancer cells, the 
concentration needed to reach 50% of the maximum cytotoxic effect (EC50) was higher in free L-BSO 
than in L-BSO@PUREG4-FA2, indicating a more effective delivery of L-BSO by the L-BSO@PUREG4-FA2 
nanoformulation in comparison to free L-BSO applied directly to the culture media (Figures 2 and 3). 
The EC50 of L-BSO@PUREG4-FA2 was 22-fold (ES2) and 81-fold (OVCAR3) lower than the EC50 of free 
L-BSO (Figures 2C,D and 3C,D). Furthermore, ES2 cells revealed to be more resistant to the L-BSO 
effect than OVCAR3, given the higher EC50 for L-BSO@PUREG4-FA2 and L-BSO in this cell line 
compared to OVCAR3 (Figures 2C,D and 3C,D).  
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Figure 2. Free L-BSO induces cell death in ovarian cancer cells in a dose dependent manner in a mM 
scale. Ovarian cancer cells (OVCAR3 and ES2) were exposed to different concentrations of L-BSO and 
cell death was determined by flow cytometry using annexin V-FITC and propidium iodide (PI) 
staining. Cell death percentage related to ES2 cells (A) and OVCAR3 cells (B) is presented. The 
concentration of L-BSO needed to reach 50% of the maximum cytotoxic effect (EC50) was also 
calculated: (C) EC50 related to ES2 cells and (D) EC50 related to OVCAR3 cells. Results are shown as 
mean ± SD.  * p ≤ 0.05 *** p ≤ 0.001 **** p ≤ 0.0001. 
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Figure 3. L-BSO@PUREG4-FA2 induces cell death in ovarian cancer cells in a dose dependent manner 
in a µM scale. Ovarian cancer cells (OVCAR3 and ES2) were exposed to different concentrations of L-
BSO loaded into PUREG4-FA2 nanoparticles (L-BSO@PUREG4-FA2) and cell death was determined by 
flow cytometry using annexin V-FITC and propidium iodide (PI) staining. Cell death percentage 
related to ES2 cells (A) and OVCAR3 cells (B) is presented. The concentration of L-BSO@PUREG4-FA2 
needed to reach 50% of the maximum cytotoxic effect (EC50) was also calculated: (C) EC50 related to 
ES2 cells and (D) EC50 related to OVCAR3 cells. Results are shown as mean ± SD.  * p ≤ 0.05  **** p ≤ 
0.0001. 
3.3. L-BSO@PUREG4-FA2 Is More Cytotoxic to Ovarian Cancer Cells than to Non-Cancer Squamous Cells  
L-BSO@PUREG4-FA2 was also tested in non-cancer squamous cells, as an attempt to address the 
effect in the peritoneal squamous cells, trying to anticipate a future therapy applied by intra-
abdominal infusion. Thus, the cell death levels in HaCaT cells were evaluated upon exposure to L-
BSO@PUREG4-FA2, and no differences were observed between cells exposed to different 
concentrations of L-BSO@PUREG4-FA2 (Figure 4). Interestingly, the highest concentration tested (1000 
µM) induced about 10% of cell death in squamous cells, whereas the same concentration induced 
more than 40% of cell death in ovarian cancer cells (Figures 3A,B and 4). This result supports that L-
BSO targeted delivery can be a good strategy to treat ovarian cancer without strongly affecting non-
cancer cells, at least in a re-sensitizing therapeutic protocol to overcome resistance to platinum salts. 
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Figure 4. L-BSO@PUREG4-FA2 does not induce cell death in non-cancer squamous cells (HaCaT). 
HaCaT cells were exposed to different concentrations of L-BSO loaded into PUREG4-FA2 nanoparticles 
(L-BSO@PUREG4-FA2) and cell death percentage was determined by flow cytometry using annexin V-
FITC and propidium iodide (PI) staining. Results are shown as mean ± SD.  
3.4. L-BSO@PUREG4-FA2 Is Effective in Increasing the Sensitivity of Ovarian Cancer Cells to Carboplatin 
To validate our re-sensitizing approach, the OVCAR3 ovarian cancer cell line was exposed to 
increasing concentrations of L-BSO@PUREG4-FA2 separately or combined with carboplatin. Overall, 
L-BSO@PUREG4-FA2 exposure improved the cytotoxic effect of carboplatin. Furthermore, L-
BSO@PUREG4-FA2 by itself increased cell death, showing again the reliance of ovarian cancer cells on 
GSH bioavailability (Figure 5). However, the highest concentrations of L-BSO@PUREG4-FA2 did not 
improve carboplatin cytotoxicity, which can be related to the threshold of cell capacity of 
internalizing nanoparticles. 
 
Figure 5. L-BSO@PUREG4-FA2 sensitizes ovarian cancer cells to carboplatin toxicity. Ovarian cancer 
cells (OVCAR3) were exposed to increased concentrations of L-BSO@PUREG4-FA2 with and without 
carboplatin (25 µg/mL). Cell death was determined by flow cytometry using annexin V-FITC and 
propidium iodide (PI) staining. Results are shown as mean ± SD. * p ≤ 0.05 **** p ≤ 0.0001. 
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4. Discussion 
Acquired chemoresistance is a critical issue in oncology and ovarian cancer is a paradigm of this 
matter. Therefore, the development of strategies to overcome chemoresistance is required for a more 
effective treatment of ovarian cancer [8,15,32,33]. Following our insights on ovarian cancer metabolic 
remodeling and therapy response [11–13], we posited that a FA-Rα-targeted delivery of L-BSO can 
be a promising strategy to revoke resistance to carboplatin (Figure 6).  
We have previously shown the efficacy of PUREG4-FA2 nanoparticles as a vehicle to deliver a 
cytotoxic selenium–chrysin compound to ovarian cancer cells [28]. In this study, we have shown the 
efficacy of those nanoparticles as a vehicle to delivery also L-BSO to ovarian cancer cells. By using 
fluorescein loaded PUREG4-FA2, we verified that ovarian cancer cells are more competent in the 
internalization of these nanoparticles when compared to non-cancer cells. The observed fluorescein 
uptake by non-cancer squamous cells at the highest tested concentration can be explained by the use 
of static cultures and by the fact that after 24 h some particles can adsorb to the cells in a nonspecific 
way. Nevertheless, our results confirmed that the high levels of FA-Rα expression by cancer cells [29] 
can be explored as a way to reduce the effect of L-BSO in non-cancerous cells. Indeed, this fact allows 
a preservative systemic therapeutic approach, since L-BSO also induces GSH depletion [34,35] in 
normal cells, thus, rendering L-BSO otherwise too toxic for therapy. In the early 1990s, L-BSO was 
used as a drug to treat cancer [36,37], but its adverse effects were so severe that its use was promptly 
interrupted. However, more recently, L-BSO has regained attention, and several studies reported the 
use of this compound in cancer preclinical models [38–42].  
 
Figure 6. Rational of L-BSO@PUREG4-FA2 sensitization to carboplatin toxicity in chemoresistant cancer 
cells. Cancer cells presenting a high glutathione (GSH) bioavailability are commonly resistant to 
platinum salts (Pt) toxicity, since GSH is a reactive oxygen species (ROS) scavenger and a xenobiotic 
detoxifying system. L-Buthionine sulfoximine (L-BSO) is an irreversible inhibitor of γ-
glutamylcysteine ligase (GCL; which has catalytic and modulator subunits, GCLC and GCLM) 
responsible for GSH synthesis. The targeted delivery of L-BSO in folate-functionalized polyurea 
dendrimer generation four (PUREG4-FA2) nanoparticles, taking advantage of the increased expression 
of FA-Rα in cancer cells, will be efficiently internalized, inhibiting the synthesis of GSH. Therefore, 
carboplatin will act through its mechanisms of action, ROS generation and adducts formation, 
culminating in cancer cells death. 
Prior to this study, we demonstrated that free L-BSO efficiently diminishes GSH bioavailability, 
impairing resistance to carboplatin [11].  Importantly, this effect of L-BSO was also observed in an in 
Antioxidants 2020, 9, 133 10 of 13 
vivo model of ovarian cancer, reducing significantly subcutaneous tumor size and GSH levels, as 
well as peritoneal dissemination [11]. In the present study, we verified that a L-BSO@PUREG4-FA2 
nanoformulation (Figure 7) is more effective in inducing ovarian cancer cells death than free L-BSO; 
and that ovarian cancer cells are more sensitive to L-BSO@PUREG4-FA2 than non-cancer squamous 
cells (HaCaT), reinforcing a putative therapy mediated by abdominal infusion. 
 
Figure 7. L-BSO@PUREG4-FA2 nanoformulation. Chemical (A) and cartoon (B) representation of the 
nanoformulation. L-BSO (green color) is encapsulated in a folate-targeted (orange color) generation 
four polyurea dendrimer (PUREG4-FA2). 
Our previous studies suggested a stronger dependence of ES2 cells on GSH turnover compared 
with OVCAR3 cells [12,13], which was also evidenced in this study, as higher EC50 of free L-BSO and 
L-BSO@PUREG4-FA2 were determined for ES2 compared with OVCAR3 cells. Furthermore, 
concerning resistance to carboplatin, we have reported that upon carboplatin exposure ES2 produce 
higher levels of GSH [11] together with an accelerated GSH turnover, compared with OVCAR3 [28]. 
Therefore, our greatest achievements in this study were the effective use of L-BSO@PUREG4-FA2 
nanoparticles to the specific targeting of malignant cells, decreasing the harmful effects of L-BSO in 
non-malignant cells, and the similar effective targeting of ovarian cancer cells with different levels of 
chemoresistance. Together, our study supports the use of L-BSO@PUREG4-FA2 nanoparticles as a 
powerful strategy for ovarian cancer treatment. 
5. Conclusions 
More validation studies, namely in vivo assays, aiming to evaluate the systemic cytotoxic effect 
of L-BSO@PUREG4-FA2, are needed. Nevertheless, our study points out this new nanoformulation as 
a way of avoiding L-BSO systemic toxicity, and as a tool to abolish cancer cells resistance to 
carboplatin or putatively to other alkylating/oxidative drugs. In the future, this approach may be 
applied to other chemoresistant cancers. 
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